Thr358
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr358  -  Myc (human)

Site Information
EENVkRRtHNVLERQ   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 450960

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 , 2 ) , mutation of modification site ( 2 , 3 ) , phospho-antibody ( 1 ) , western blotting ( 1 , 2 )
Disease tissue studied:
bone cancer ( 2 ) , Ewing's sarcoma ( 2 ) , leukemia ( 3 ) , acute myelogenous leukemia ( 3 ) , ovarian cancer ( 2 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
PAK2 (human) ( 3 )

Downstream Regulation
Effects of modification on Myc:
molecular association, regulation ( 1 , 3 )
Effects of modification on biological processes:
carcinogenesis, inhibited ( 3 ) , cell differentiation, induced ( 3 ) , transcription, induced ( 1 , 3 )
Induce interaction with:
DNA ( 3 )
Inhibit interaction with:
DNA ( 1 ) , MAX (human) ( 1 )

References 

1

von Eyss B, et al. (2015) A MYC-Driven Change in Mitochondrial Dynamics Limits YAP/TAZ Function in Mammary Epithelial Cells and Breast Cancer. Cancer Cell 28, 743-57
26678338   Curated Info

2

Mei Z, et al. (2015) FBXO32 Targets c-Myc for Proteasomal Degradation and Inhibits c-Myc Activity. J Biol Chem 290, 16202-14
25944903   Curated Info

3

Uribesalgo I, et al. (2011) E-box-independent regulation of transcription and differentiation by MYC. Nat Cell Biol 13, 1443-9
22020439   Curated Info